# Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I)

> **NCT03093974** · PHASE3 · COMPLETED · sponsor: **Zambon SpA** · enrollment: 377 (actual)

## Conditions studied

- Non Cystic Fibrosis Bronchiectasis

## Interventions

- **DRUG:** CMS
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03093974
- **Lead sponsor:** Zambon SpA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-06
- **Primary completion:** 2021-04-09
- **Final completion:** 2021-04-09
- **Target enrollment:** 377 (ACTUAL)
- **Last updated:** 2023-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03093974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03093974, "Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03093974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*